You are here: Home / API / Hot APIs / Entecavir(142217-69-4)C12H15N5O3

Entecavir(142217-69-4)C12H15N5O3

  • Chemical Name: Entecavir
  • CAS No.:1 42217-69-4
  • MF: C12H15N5O3
  • MW: 277.28
  • Purity: ≥98% or according to customer requested
  • Color: white to beige
  • Product Categories: Pharmaceutical raw materials;APIs;Synthetic Anti-infective Drugs
  • Test method: HPLC
Availability:

What is Entecavir?

Entecavir Anhydrous is an anhydrous formulation of entecavir, a synthetic analog of 2-deoxyguanosine with antiviral activity against hepatitis B virus (HBV). Entecavir is activated in vivo to a 5-triphosphate metabolite. In turn, the triphosphate form competes with the natural substrate deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA. The incorporation of the activated triphosphate metabolite of entecavir inhibits the reverse transcriptase (RT) viral RNA-dependent HBV DNA polymerase and, so, the replication of viral DNA and transcription.

Basic information
           
Product Name: Entecavir
Synonyms: Entecavir USP; Entecavir INN
CAS: 142217-69-4
MF: C12H15N5O3
MW: 277.28
EINECS: 604-279-5
Product Categories: >Pharmaceutical raw materials; APIs; Synthetic Anti-infective Drugs
Chemical Structure

Entecavir            

Chemical Properties           

Melting point: 249-252°C    

Boiling point: 661.4±65.0 °C(Predicted)    

density: 1.81±0.1 g/cm3(Predicted)    

storage temp.: -20°C    

pka: 14.22±0.60(Predicted)    

form: powder    

color:white to beige    

Entecavir Uses

Entecavir is a guanosine nucleoside analogue used in the treatment of chronic hepatitis B virus (HBV) infection. Entecavir therapy can be associated with flares of the underlying hepatitis B during or after therapy, but has not been linked to cases of clinically apparent liver injury.

Patients with chronic hepatitis B should be under the guidance of experienced doctors taking this product. Recommended dosage: adult and over the age of 16 young oral this product, once a day, each 0.5 mg. lamivudine treatment viremia or patients with lamivudine resistant mutants to once a day, each 1.0 mg (0.5mg two pieces), taken on an empty stomach (a meal or a meal after at least 2 hours).


Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

MSDS: MSDS available.

COA: COA can be available if you send us inquiry.

Email us at: info@maxmedchem.com for more details.

packagingpacking&shipping

LEAVE MESSAGE

Active Pharmaceutical Ingredients (APIs)& Pharma intermediates Supplier

MAPS

ABOUT US

Maxmedchem Corporation, was founded in 2004 and is the one of top manufacturers of Active Pharmaceutical Ingredients (APIs), and intermediates.

CONTACT US

Add : 1901 S.Lynx Place, Ontario, CA 91761
Phone : +16263716327
Copyright © 2021 MAXMEDCHEM Co. Ltd. All rights reserved. | Sitemap